Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b

Ophthalmology. 2008 Aug;115(8):1291-6, 1296.e1. doi: 10.1016/j.ophtha.2007.10.039. Epub 2008 Jan 9.


Objective: To evaluate the long-term recurrence rate (>1 year) of conjunctival and corneal intraepithelial neoplasia (CIN) treated with topical interferon alfa-2b.

Design: Retrospective, noncomparative, interventional case series.

Participants: Twenty-eight eyes of 26 patients from 2 institutions, treated between April 1997 and June 2005, with CIN lesions utilized topical interferon alfa-2b drops 4 times daily until clinical resolution was achieved.

Methods: Patients' charts and clinical photographs were reviewed, and data were analyzed.

Main outcome measures: All eyes were monitored for the possibility of recurrence with a minimum of 1-year follow-up from the time of documented clinical resolution.

Results: Complete clinical resolution of the CIN lesions was achieved in 27 of the 28 eyes treated (96.4%). One of the 28 eyes treated (3.6%) had only a partial response to treatment. For the 27 eyes with complete response, resolution occurred after a median of 2.0 months (range, 10 days-15 months). Eyes were treated for a median of 3.2 months (range, 1-15). Median follow-up after clinical resolution (tumor-free period) was 42.4 months (range, 14-89). One eye of the 27 analyzed (3.7%) experienced a recurrence. Side effects of treatment were limited to mild conjunctival hyperemia and follicular conjunctivitis in 3 patients (12%). In all cases, there was total resolution of the side effects within 1 month after cessation of the medication.

Conclusions: In this group of patients with CIN lesions observed for >1 year, topical interferon alfa-2b was effective in treating lesions with minimal self-limited side effects.

Publication types

  • Multicenter Study

MeSH terms

  • Administration, Topical
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma in Situ / drug therapy*
  • Carcinoma in Situ / pathology
  • Conjunctival Neoplasms / drug therapy*
  • Conjunctival Neoplasms / pathology
  • Corneal Diseases / drug therapy*
  • Corneal Diseases / pathology
  • Eye Neoplasms / drug therapy*
  • Eye Neoplasms / pathology
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Recombinant Proteins
  • Retrospective Studies
  • Treatment Outcome


  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins